Article metrics

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial

 

Online download statistics by month:

Online download statistics by month: October 2021 to June 2022

AbstractFullPdf
Oct 2021789789307
Nov 2021422417167
Dec 2021281271127
Jan 202220520788
Feb 202214114776
Mar 202220922295
Apr 202225926475
May 202218118287
Jun 202214414464
Total263126431086